Korean J Intern Med > Volume 34(2); 2019 > Article |
|
Characteristic | RA with ILD (n = 77) | RA without ILD (n = 231) | p value |
---|---|---|---|
Age, yr | 56.6 ± 13.1 | 57.1 ± 11.7 | 0.731a |
Female sex | 58 (75.3) | 174 (75.3) | 1.000b |
Disease duration, yr | 11.5 ± 8.5 | 10.8 ± 6.9 | 0.458a |
Smoking | |||
Ex-smoker | 10/68 (14.7) | 18/152 (11.8) | 0.162b |
Current smoker | 4/68 (5.9) | 7/152 (4.6) | 0.367c |
Pack-years | 28.4 ± 19.8 | 33.7 ± 15.4 | 0.445a |
History of tuberculosis or NTM | 12 (15.6) | 16 (6.9) | 0.022b |
Serology | |||
RF positivity | 56/76 (73.7) | 160/227 (70.5) | 0.838b |
RF titer | 521.1 ± 828.3 | 249.3 ± 332.4 | 0.001a |
Anti-CCP positivity | 33/43 (76.7) | 95/142 (66.9) | 0.335b |
Anti-CCP titer | 242.8 ± 234.4 | 125.3 ± 144.3 | 0.001a |
Baseline ESR, mm/hr | 59.9 ± 37.3 | 44.9 ± 35.1 | 0.193a |
Baseline CRP, mg/L | 29.5 ± 35.3 | 19.1 ± 29.5 | 0.014a |
Presence of erosion on joint X-rays at baseline | 77 (33.3) | 15 (19.5) | 0.125b |
Medication | 77 | 231 | |
Methotrexate | 30 (39.0) | 176 (76.2) | < 0.001b |
Leflunomide | 22 (28.6) | 60 (26.1) | 0.670b |
Hydroxychloroquine | 46 (59.7) | 147 (63.6) | 0.540b |
Sulfasalazine | 48 (63.2) | 73 (32.0) | < 0.001b |
Tacrolimus | 2 (2.6) | 6 (2.6) | 0.991c |
TNF inhibitor | 4 (5.2) | 12 (5.2) | 1.000c |
Rituximab | 2 (2.6) | 0 | < 0.001c |
Characteristic | RA with ILD (n = 77) | Death (n = 28) | Alive (n = 49) | p value |
---|---|---|---|---|
Age at the time of ILD diagnosis | 59.0 ± 13.3 | 64.1 ± 10.4 | 56.3 ± 11.7 | 0.314a |
Female sex | 58 (75.3) | 17 (60.7) | 41 (83.7) | 0.025b |
Smoking | ||||
Ex-smoker | 10/68 (14.7) | 6/27 (22.2) | 4/41 (9.7) | 0.096c |
Current smoker | 4/68 (5.9) | 2/27 (7.4) | 2/41 (4.9) | 0.560c |
Pack-years | 28.4 ± 19.8 | 21.4 ± 12.1 | 42.5 ± 26.3 | 0.154a |
Serology | ||||
RF positivity | 5/76 (73.7) | 23/28 (82.1) | 34/48 (70.8) | 0.161b |
RF titer | 521.1 ± 828.3 | 774.5 ± 1,112.9 | 345.2 ± 506.4 | 0.001a |
Anti-CCP positivity | 33/43 (76.7) | 9/13 (69.2) | 24/30 (80.0) | 0.151b |
Anti-CCP titer | 242.8 ± 234.4 | 189.4 ± 224.5 | 263.4 ± 239.1 | 0.368a |
Mean ESR, mm/hr | 47.9 ± 25.5 | 58.0 ± 25.0 | 42.2 ± 24.3 | 0.008a |
Mean CRP, mg/L | 31.7 ± 21.9 | 37.2 ± 37.8 | 25.1 ± 33.5 | 0.009a |
Medication | ||||
Methotrexate | 30 (39.0) | 8 (28.6) | 22 (45.8) | 0.138b |
Leflunomide | 22 (28.6) | 7 (25.0) | 15 (31.3) | 0.562b |
Hydroxychloroquine | 46 (59.7) | 17 (60.7) | 29 (60.4) | 0.980b |
Sulfasalazine | 48 (63.2) | 16 (57.1) | 32 (66.7) | 0.406b |
Tacrolimus | 2 (2.6) | 1 (3.6) | 1 (2.1) | 0.696c |
TNF inhibitor | 4 (5.2) | 1 (3.6) | 3 (6.3) | 0.614c |
Rituximab | 2 (2.6) | 1 (3.6) | 1 (2.1) | 0.696c |
Mean corticosteroid dose, mg/day | 6.7 ± 7.6 | 7.1 ± 8.3 | 6.4 ± 7.3 | 0.730a |
Baseline lung function | ||||
FVC, L | 2.34 ± 0.72 | 2.32 ± 0.78 | 2.35 ± 0.69 | 0.304c |
Predicted, % | 81.2 ± 19.7 | 80.0 ± 19.9 | 81.9 ± 19.9 | 0.739c |
DLCO | 14.06 ± 25.95 | 10.15 ± 3.13 | 16.23 ± 32.20 | 0.249c |
Predicted, % | 68.0 ± 20.3 | 64.5 ± 21.6 | 70.1 ± 19.5 | 0.600c |
Subtypes on HRCT | ||||
NSIP | 17/67 (25.4) | 1/26 (3.8) | 16/41 (39.0) | 0.001c,d |
OP | 13/67 (19.4) | 5/26 (19.2) | 8/41 (19.5) | 0.489b |
UIP | 32/67 (47.8) | 19/26 (73.1) | 13/41 (31.7) | 0.001b,d |
DPB | 2/67 (3.0) | 0/26 (0.0) | 2/41 (4.9) | 0.371c |
LIP | 2/67 (3.0) | 0/26 (0.0) | 2/41 (4.9) | 0.371c |
DIP | 1/67 (1.5) | 1/26 (3.8) | 0/41 (0.0) | 0.388c |
Histopathology on lung biopsy | ||||
NSIP | 4/16 (25.0) | 0/4 (0.0) | 4/12 (30.0) | 0.272c |
OP | 2/16 (12.5) | 1/4 (25.0) | 1/12 (8.3) | 0.450c |
UIP | 7/16 (43.8) | 2/4 (50.0) | 5 /12(41.7) | 0.608c |
DPB | 1/16 (6.3) | 0/4 (0.0) | 1/12 (8.3) | 0.750c |
LIP | 1/16 (6.3) | 0/4 (0.0) | 1/12 (8.3) | 0.750c |
DIP | 1/16 (6.3) | 1/4 (25.0) | 0/12 (0.0) | 0.250c |
Values are presented as mean ± SD or number (%).
RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; TNF, tumor necrosis factor; FVC, forced vital capacity; DLCO, diffusing capacity of carbon monoxide; HRCT, high-resolution computed tomography; NSIP, nonspecific interstitial pneumonia; OP, organizing pneumonia; UIP, usual interstitial pneumonia; DPB, diffuse panbronchiolitis; LIP, lymphocytic interstitial pneumonia; DIP, desquamative interstitial pneumonia.
Impact of early diagnosis on functional disability in rheumatoid arthritis2017 July;32(4)